ClinicalTrials.Veeva

Menu

Evaluating Surface Area Reduction Using MolecuLight Imaging Device

C

Calver Pang

Status

Unknown

Conditions

Wound
Wound Infection

Treatments

Procedure: Wound care
Device: MolecuLight i:X™ Imaging Device

Study type

Interventional

Funder types

Other

Identifiers

NCT03181568
BTHFT 2159

Details and patient eligibility

About

12-week single-blind, prospective, randomized, controlled, pilot clinical trial assessing The MolecuLight i:X Imaging Device in chronic wounds. This device guides clinicians to inspect, sample, debride or further evaluate areas within or around a wound where potentially harmful bacteria appear under violet light illumination resulting in better overall care and accelerated surface area reduction compared to current standard care. The study aims to determine if this device aids in the healing of chronic wounds by reduction in size of wound compared to current standard of care.

Full description

This is a prospective, 12-week, single-blinded, randomized, controlled clinical trial has been designed with two primary objectives needed to inform more comprehensive studies at a later date. We propose to evaluate the following two primary outcomes: (1) the ability of the MolecuLight i:X Imaging Device to predict non healing wounds and wounds at risk or infection (control arm) and (2) whether utilization of the MolecuLight i:X Imaging Device in guiding clinicians to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present (treatment arm) increases wound healing rates relative to standard care (control arm) for the treatment of chronic wounds.

Both arms will receive standard procedures associated with wound care (e.g., sampling, debridement, preventative care, infection control, etc.) according to best practice guidelines. Patients will be randomly assigned to either the control or treatment arm and be followed as per the study protocol every time their wound is cared for over a 12-week period. The effectiveness of the MolecuLight i:X Imaging Device will be assessed with evaluation of wound surface area reduction rate and infection rates (incidence of infection and time to eradicate infection) compared to standard care.

All subjects randomized will be evaluated for 12 weeks from the date of enrollment and treatment initiation. Subjects who may have wound closure within the 12-week study period will continue to have scheduled study evaluation visits up to the end of week 12.

Enrollment

80 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. age ≥ 18 years
  2. having a chronic wound that is not a diabetic foot ulcer
  3. presence of the wound for ≥ 6 weeks and ≤ 2 years.
  4. wound size surface area ≥ 2 cm2 and ≤ 50 cm2.
  5. Willingness to comply with prescribed wound care regimen

Exclusion criteria

  1. candidate for surgery in the next 12 weeks
  2. a wound with necrotic tissue unable to tolerate debridement
  3. uncontrolled diabetics (defined as HbA1c of >85.5mmol/mol)
  4. presence of a diabetic foot ulcer
  5. currently taking medication that may interfere with wound healing (e.g., oral systemic steroids, immunosuppressive drugs, unfractionated heparin infusion)
  6. women who are currently pregnant or are breast feeding; or women of child bearing potential who are not currently taking adequate birth control
  7. participation in another investigative drug or device trial currently or within the last 30 days

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

80 participants in 2 patient groups

Control
Other group
Description:
This arm group (control) will receive standard wound care of chronic wounds
Treatment:
Procedure: Wound care
Treatment
Other group
Description:
The treatment arm of the study will utilize the MolecuLight i:X Imaging Device to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present
Treatment:
Device: MolecuLight i:X™ Imaging Device

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems